Protocol Ledger

NCT05456256 · Phase II · RECRUITING

A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma

Interventional Phase II clinical trial protocol NCT05456256 sponsored by Lantern Pharma in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-03-01 Enrollment: 90 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05456256
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)90 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05456256
Protocol FieldVerified Registry Value
NCT IdentifierNCT05456256
Consolidated Lead SponsorLantern Pharma
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment90 participants (ESTIMATED)
Registered Start Date2023-03-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05456256
Hospital Research SiteLocationSite Profile
Fox Chase Cancer CenterPhiladelphia, PAOpen Hospital Dossier ->
UT Southwestern Simmons Cancer CenterDallas, TXOpen Hospital Dossier ->
Tohoku University HospitalSendai, JapanOpen Hospital Dossier ->
Okayama University HospitalOkayama, JapanOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI